Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study

By afschroeder • April 17, 2026

Kim YJ, Merle P, Finn RS, Klümpen HJ, Lim HY, Ikeda M, Granito A, Masi G, Gerolami R, Pinter M, Babajanyan S, Twumasi-Ankrah P, Ghadessi M, Ozgurdal K, Qin S. Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study. ESMO Gastrointest Oncol. 2026 Jan 22;11:100292. doi: 10.1016/j.esmogo.2025.100292. PMID: 41994011; PMCID: PMC13080904.

Tags: Hematology/Oncology, Hepatocellular carcinoma, observational, prospective, Publications, real-world evidence, regorafenib, subgroup analysis

Related Posts

Impact of metastatic pattern and histologic subtype on PD-(L)1 inhibitor efficacy in HER2-negative advanced gastric and gastroesophageal cancer: a meta-analysis

Tai D, Kim KI, Shah P, Park D, Kim L, Li J, Jung C, Guzman S, Brar G, Wu S, Castillo D. Impact of metastatic[...]

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Srour SA, Chahoud J, Drakaki A, Curti BD, Gibney GT, Tang L, Jiang Y, Charmsaz S, Robbins PB, McLeroy J, Severyn CJ, Le Gall JB,[...]

Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD

Goldberg SB, Ahn MJ, Baik C, De Castro Carpeño J, Cho BC, de Langen AJ, Fidler MJ, Goldman JW, Grønberg BH, Akamatsu H, Kim SW,[...]